New Imaging Method May Identify Ovarian Cancer Patients Likely to Benefit From PARP Inhibitors

New Imaging Method May Identify Ovarian Cancer Patients Likely to Benefit From PARP Inhibitors
A new imaging method aims to identify ovarian cancer patients most likely to benefit from treatment with PARP-1 inhibitors — a drug class being developed for people with mutations in the BRCA1 gene. Researchers at the University of Pennsylvania’s Perelman School of Medicine presented their study, “Exploring the significance of PARP-1 expression for therapy and clinical PET/CT imaging

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *